{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:08:05Z","timestamp":1789013285913,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.yebeh.2026.111208","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:16:51Z","timestamp":1784776611000},"page":"111208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Valproate vs levetiracetam in juvenile myoclonic epilepsy: systematic review and meta-analysis"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0970-8453","authenticated-orcid":false,"given":"Lav\u00ednia Voss","family":"Agra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela Caracas","family":"Machado Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Carlos Fonseca","family":"de Azevedo Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Montenegro Ten\u00f3rio","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia Agra","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz P.","family":"Aguiar-Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Beltr\u00e3o","family":"Br\u00eada-Cavalcante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo F.O","family":"Suruagy-Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Costa","family":"Guido Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Leticia Amorim","family":"de Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Alves","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Ten\u00f3rio","family":"Gameleira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orrin","family":"Devinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2026.111208_b0010","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.yebeh.2019.05.021","article-title":"Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy","volume":"98","author":"Landmark","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2026.111208_b0030","doi-asserted-by":"crossref","DOI":"10.4045\/tidsskr.11.1518","article-title":"Juvenil myoklonusepilepsi","author":"Syvertsen","year":"2012","journal-title":"Tidsskrift for Den norske legeforening"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111208_b0005","first-page":"617","article-title":"Efficacy of levetiracetam, lamotrigine and sodium valproate on seizure attacks and EEG disorders in patients with juvenile myoclonic epilepsy: a double blind randomized clinical trial","volume":"13","author":"Daneshyar","year":"2022","journal-title":"Caspian J Intern Med"},{"issue":"6","key":"10.1016\/j.yebeh.2026.111208_b0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/WNF.0000000000000177","article-title":"Levetiracetam and valproate retention rate in juvenile myoclonic epilepsy","volume":"39","author":"Sala-padr\u00f3","year":"2016","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111208_b0020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40263-018-00602-2","article-title":"Treatment of juvenile myoclonic epilepsy in patients of child-bearing potential","volume":"33","author":"Serafini","year":"2019","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111208_b0025","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.seizure.2007.07.001","article-title":"Levetiracetam monotherapy in juvenile myoclonic epilepsy","volume":"17","author":"Sharpe","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2026.111208_b0035","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2026.111208_b0040","unstructured":"RAYYAN. Rayyan: Intelligent systematic review. Doha: Qatar Computing Research Institute (QCRI), 2016."},{"key":"10.1016\/j.yebeh.2026.111208_b0045","doi-asserted-by":"crossref","unstructured":"SCHARDT C. et al. \u201cUtilization of the PICO Framework to Improve Searching PubMed for Clinical Questions,\u201d BMC Medical Informatics and Decision Making 7, no. 1, 2007.","DOI":"10.1186\/1472-6947-7-16"},{"key":"10.1016\/j.yebeh.2026.111208_b0050","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ, Londres"},{"key":"10.1016\/j.yebeh.2026.111208_b0055","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ, Londres"},{"key":"10.1016\/j.yebeh.2026.111208_b0060","doi-asserted-by":"crossref","unstructured":"Schwarzer G, Carpenter JR, R\u00fccker G. Meta-Analysis with R. Cham: Springer International Publishing; 2015.","DOI":"10.1007\/978-3-319-21416-0"},{"key":"10.1016\/j.yebeh.2026.111208_b0075","first-page":"1","article-title":"Valproate-induced reversible cognitive decline presenting as dementia and associated clinical features: a literature review","volume":"110","author":"Alsukhni","year":"2023","journal-title":"Seizure: Eur J Epilepsy"},{"key":"10.1016\/j.yebeh.2026.111208_b0080","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40263-025-01231-2","article-title":"Effects of antiseizure medications on lipid profile and weight in patients with epilepsy: a systematic review with meta-analysis","volume":"39","author":"Chocho\u0142","year":"2025","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.yebeh.2026.111208_b0085","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m15008","article-title":"Associations of valproate doses with weight gain in adult psychiatric patients: a 1-year prospective cohort study","volume":"85","author":"Grosu","year":"2024","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111208_b0065","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/epi4.12349","article-title":"Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy","volume":"4","author":"Silvennoinen","year":"2019","journal-title":"Epilepsia Open"},{"issue":"2","key":"10.1016\/j.yebeh.2026.111208_b0070","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/epi4.12321","article-title":"Clinical features and treatment outcomes of Juvenile myoclonic epilepsy patients","volume":"4","author":"Zhang","year":"2019","journal-title":"Epilepsia Open"},{"issue":"7","key":"10.1016\/j.yebeh.2026.111208_b0090","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1059-1311(00)90530-2","article-title":"Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate","volume":"9","author":"Calleja","year":"2001","journal-title":"Seizure: Eur J Epilepsy"},{"key":"10.1016\/j.yebeh.2026.111208_b0095","doi-asserted-by":"crossref","unstructured":"World Health Organization. WHO Model List of Essential Medicines \u2013 23rd List. Geneva: WHO; 2023.","DOI":"10.1530\/ey.19.13.1"},{"issue":"9","key":"10.1016\/j.yebeh.2026.111208_b0100","first-page":"1077","article-title":"Central nervous system adverse effects of new antiepileptic drugs: a meta\u2011analysis of placebo\u2011controlled studies","volume":"43","author":"Geller","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.111208_b0105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.seizure.2021.08.019","article-title":"Treatment outcomes in drug resistant juvenile myoclonic epilepsy: Valproate resistance may not be the end of the road","volume":"92","author":"Baheti","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2026.111208_b0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.seizure.2022.05.005","article-title":"Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: a retrospective multi-center study from Turkey between 2010 and 2020","volume":"99","author":"Kili\u00e7","year":"2022","journal-title":"Seizure: Eur J Epilepsy"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502600329X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502600329X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:27:57Z","timestamp":1789010877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502600329X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":22,"alternative-id":["S152550502600329X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.111208","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproate vs levetiracetam in juvenile myoclonic epilepsy: systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.111208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111208"}}